^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE4 inhibitor

    Related drugs:
    16h
    Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE) (clinicaltrials.gov)
    P4, N=1032, Completed, Johns Hopkins University | Active, not recruiting --> Completed
    Trial completion
    |
    roflumilast
    7d
    A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. (clinicaltrials.gov)
    P1, N=160, Recruiting, Guangdong Hengrui Pharmaceutical Co., Ltd | N=82 --> 160 | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    11d
    On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies. (PubMed, J Dermatolog Treat)
    At 12, 18, and 24 months after the start of the maintenance phase, respectively, on-label persistence was 190%, 180%, and 179% more likely on guselkumab versus SC TNFi; 78%, 87%, and 91% more likely on guselkumab versus SC IL-17i; and 187%, 199%, and 193% more likely on guselkumab versus apremilast (all p < 0.001). Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.
    Clinical • Retrospective data • Journal
    |
    IL17A (Interleukin 17A)
    12d
    A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Palisade Bio
    New P1 trial • First-in-human
    12d
    RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (clinicaltrials.gov)
    P2/3, N=460, Completed, University Health Network, Toronto | Suspended --> Completed
    Trial completion
    |
    Eyevinal (ibudilast)
    15d
    Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD: A Multicenter, Single-Arm, Open-Label Study (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P2 trial
    17d
    PREMS: Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis (clinicaltrials.gov)
    P3, N=134, Recruiting, University Hospital, Rouen | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Dec 2026 | Trial primary completion date: Jun 2027 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    24d
    The Safety and Efficacy of Roflumilast Foam in HS (clinicaltrials.gov)
    P2, N=20, Recruiting, Beth Israel Deaconess Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    29d
    MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, MediciNova | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial primary completion date
    1m
    Apremilast for Alcohol Use Disorder Treatment in Women and Men (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Yale University | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    1m
    Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Yale University | Initiation date: Nov 2025 --> Mar 2026
    Trial initiation date
    1m
    A phase II clinical Trial on the efficacy and safety of TQC3721 inhalation powder (ChiCTR2500112449)
    P2, N=195, Not yet recruiting, West China Hospital, Sichuan University; Chia Tai Tianqing Pharmaceutical Group Co., Ltd
    New P2 trial